[1] Panacos Pharmaceuticals, Inc. - Pipeline: Bevirimat. Available at: http://www.panacos.com/product_2.htm. Accessed 03/10/08. [2] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 256. [3] AIDSNews - PA-457, New Kind of Antiretroviral: Ten-Day Clinical Trial Results. Available at: http://www.aidsnews.org/2005/09/pa-457.html. Accessed 03/10/08. [4] Panacos Pharmaceuticals, Inc. - Pipeline: Bevirimat. Available at: http://www.panacos.com/product_2.htm. Accessed 03/10/08. [5] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 159. [6] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 159. [7] Conf Retroviruses Opportunistic Infect - 11th, 2004. Abstract 551. [8] Panacos Pharmaceuticals, Inc. - Pipeline: Bevirimat. Available at: http://www.panacos.com/product_2.htm. Accessed 03/10/08. [9] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces First Cohort Results of Phase 2b Study [Press Release], December 19, 2006. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [10] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Bevirimat Phase 2 Dose Escalation Strategy [Press Release], March 12, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [11] Interscience Conf on Antimicrobial Agents and Chemotherapy - 48th, 2008. Abstract H-891. [12] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 159. [13] Int Conf AIDS - 15th, 2004. Abstract WePeA5643. [14] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 256. [15] Conf Retroviruses Opportunistic Infect - 11th, 2004. Abstract 545. [16] Int Conf AIDS - 15th, 2004. Abstract WePeA5643. [17] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 159. [18] Conf Retroviruses Opportunistic Infect - 11th, 2004. Abstract 545. [19] IAS Conf on HIV Pathogenesis and Treatment - 3rd, 2005. Abstract TuPe3.1B01. [20] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 551. [21] Intersci Conf Antimicrob Agents Chemother - 45th, 2005. Presentation H-416d. [22] Intersci Conf Antimicrob Agents Chemother - 45th, 2005. Presentation A-1149. [23] Int Conf AIDS - 16th, 2006. Abstract CDA0140. [24] Conf Retroviruses Opportunistic Infect - 11th, 2004. Abstract 545. [25] IAS Conf on HIV Pathogenesis and Treatment - 3rd, 2005. Abstract TuPe3.1B01. [26] Conf Retroviruses Opportunistic Infect - 13th, 2006. Abstract 509. [27] Conf Retroviruses Opportunistic Infect - 13th, 2006. Abstract 156. [28] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Substantial Antiviral Response in Bevirimat 250 mg Cohort, Data Support Further Dose Escalation in Phase 2b Study [Press Release], May 29, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [29] Conf Retroviruses Opportunistic Infect - 15th, 2008. Abstract 859. [30] Interscience Conf on Antimicrobial Agents and Chemotherapy - 48th, 2008. Abstract H-891. [31] Int Conf AIDS - 15th, 2004. Abstract WePeA5644. [32] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 159. [33] Interscience Conf on Antimicrobial Agents and Chemotherapy - 45th, 2005. Presentation H-416d. [34] Interscience Conf on Antimicrobial Agents and Chemotherapy - 45th, 2005. Presentation A-1149. [35] Interscience Conf on Antimicrobial Agents and Chemotherapy - 48th, 2008. Abstract H-891. [36] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Initiation of Phase 2b Clinical Trial of First-In-Class HIV Maturation Inhibitor, Bevirimat (PA-457) [Press Release], June 12, 2006. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [37] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces First Cohort Results of Phase 2b Study [Press Release], December 19, 2006. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [38] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Bevirimat Phase 2b Dose Escalation Strategy [Press Release], March 12, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [39] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Substantial Antiviral Response in Bevirimat 250 mg Cohort, Data Support Further Dose Escalation in Phase 2b Study [Press Release], June 20, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [40] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Greater than 1 Log10 Mean Reduction in 300 mg Bevirimat Cohort [Press Release], October 25, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [41] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Results of Bevirimat 350 mg Cohort, Data Support Further Dose Escalation in Phase 2b Study [Press Release], December 10, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [42] Natap.org - Safety and Antiviral Activity of PA-457, the First-In-Class Maturation Inhibitor in a 10-Day Monotherapy Study in HIV-1 Infected Patients. Conference Reports for NATAP: ICAAC 2005; Washington, DC. Available at: http://www.natap.org/2005/ICAAC/icaac_3.htm. Accessed 03/10/08. [43] Conf Retroviruses Opportunistic Infect - 12th, 2005. Abstract 159. [44] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Greater than 1 Log10 Mean Reduction in 300 mg Bevirimat Cohort [Press Release], October 25, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [45] Panacos Pharmaceuticals, Inc. - News and Events: Press Releases. Panacos Announces Results of Bevirimat 350 mg Cohort, Data Support Further Dose Escalation in Phase 2b Study [Press Release], December 10, 2007. Available at: http://www.panacos.com/ne_press_releases.htm. Accessed 03/10/08. [46] Conf Retroviruses Opportunistic Infect - 11th, 2004. Abstract 545. [47] Conf Retroviruses Opportunistic Infect - 13th, 2006. Abstract 509. [48] Intersci Conf Antimicrob Agents Chemother - 46th, 2006. Abstract A/377. [49] MeSH - Available at: http://www.nlm.nih.gov/mesh/Mbrowser.html. Accessed 03/10/08. [50] Proc Natl Acad Sci USA - 2003 Nov 11;100(23):13555-60 [51] Proc Natl Acad Sci USA - 2003 Nov 11;100(23):13555-60 [52] Proc Natl Acad Sci USA - 2003 Nov 11;100(23):13555-60 [53] Intersci Conf Antimicrob Agents Chemother - 46th, 2006. Abstract A/377. [54] Panacos Pharmaceuticals, Inc. - Bevirimat (PA-457). Available at: http://www.panacos.com/product_2.htm. Accessed 03/10/08.
|